Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
  • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
  • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/08—Drugs for disorders of the urinary system of the prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
  • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
  • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
  • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D261/12—Oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
  • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
  • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D263/36—One oxygen atom
  • C07D263/38—One oxygen atom attached in position 2
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D277/34—Oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
  • C07D277/62—Benzothiazoles
  • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

Definitions

• the present invention relates to new carboxylic acid derivatives, their preparation and use.
• Endothelin is a 21 amino acid peptide that is synthesized and released by vascular endothelium. Endothelin exists in three isoforms, ET-1, ET-2 and ET-3. In the following, "endothelin” or “ET” denotes one or all isoforms of endothelin. Endothelin is a potent vasoconstrictor and has a strong effect on vascular tone. This vasoconstriction is known to be caused by the binding of endothelin to its receptor (Nature, 332, 411-415, 1988; FEBS Letters, 231, 440-444, 1988 and Bioche. Biophys. Res. Commun., 154, 868-875, 1988).
• endothelin causes persistent vascular contraction in peripheral, renal, and cerebral blood vessels, which can lead to disease.
• endothelin is involved in a number of diseases. These include: hypertension, acute myocardial infarction, pulmonary hypertension, Raynaud's syndrome, cerebral vasospasm, stroke, benign prostate hypertrophy, atherosclerosis, asthma and prostate cancer (J. Vascular Med. Biology 2, 207 (1990), J. Am. Med. Association ____, 2868 (1990), Nature 344, 114 (1990), N. Engl. J. Med. 122, 205 (1989), N. Engl. J. Med.
• ET A and ET B receptor At least two endothelin receptor subtypes, ET A and ET B receptor, are currently described in the literature (Nature 348, 730 (1990), Nature 348, 732 (1990)). Accordingly, substances that inhibit the binding of endothelin to one or both receptors should antagonize the physiological effects of endothelin and should therefore be valuable pharmaceuticals.
• the task was to provide endothelin receptor antagonists that bind to the ET A and / or the ET B receptor.
• the invention relates to heterocyclically substituted ⁇ -hydroxycarboxylic acid derivatives of the formula I.
• R 1 stands for tetrazole or for a group
• Hydrogen the cation of an alkali metal, the cation of an alkaline earth metal, a physiologically compatible organic ammonium ion such as tertiary C 1 -C 4 -alkylammonium or the ammonium ion;
• R 5 can also be a phenyl radical which can carry one to five halogen atoms and / or one to three of the following radicals: nitro, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxy, C 1 -C 4 alkoxy , Mercapto, C 1 -C 4 alkylthio, amino, NH (C 1 -C 4 alkyl), N (C 1 -C 4 alkyl) 2 .
• a 5-membered heteroaromatic linked via a nitrogen atom such as pyrrolyl, pyrazolyl, imidazolyl and triazolyl, which can carry one to two halogen atoms, or one to two C 1 -C alkyl or one to two C 1 -C alkoxy groups.
• a group such as pyrrolyl, pyrazolyl, imidazolyl and triazolyl, which can carry one to two halogen atoms, or one to two C 1 -C alkyl or one to two C 1 -C alkoxy groups.
• k can take on the values 0, 1 and 2
• p can take on the values 1, 2, 3 and 4 and R 6 for
• -C-C 4 alkyl C 3 -C 8 cycloalkyl, C 3 -C 8 alkenyl, C 3 -C 8 alkynyl or phenyl, which can be mono- to trisubstituted by: halogen, nitro, cyano, C ⁇ -C-alkyl, hydroxy, C ! -C 4 -alkoxy, C alkylthio, amino, NH (C ⁇ -C4 alkyl), N (C ⁇ -C alkyl) 2, mercapto.
• R 7 means:
• R 2 and R 3 (which may be the same or different): Phenyl or Nap hyl, which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxy, mercapto, C ⁇ -C-alkyl, C 2 -C alkenyl, C 2 -C alkynyl, C ⁇ -C_Halogenalkyl , C ⁇ -C 4 alkoxy, phenoxy, C ⁇ -C 4 haloalkoxy, C ⁇ -C 4 alkylthio, amino, NH (C ⁇ -C 4 alkyl), N (C ⁇ -C 4 alkyl) 2 or phenyl, that C ⁇ -C may be mono- substituted or polysubstituted, for example mono- to trisubstituted by halogen, nitro, cyano, C _ alkyl, C ⁇ -C haloalkyl, C ⁇ -C4-alkoxy, C ⁇ -4 -haloalkoxy or C
• Phenyl or naphthyl which are ortho-linked via a direct bond, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an S0 2 , NH or N (C ⁇ -C 4 -alkyl) group;
• C 5 -C 6 cycloalkyl where these radicals can each be mono- or polysubstituted by: halogen, hydroxy, mercapto, carboxy, nitro, cyano, C 1 -C 4 -alkyl, C 2 -C 4 alkenyl, C 2 -C 4 -alkynyl, -CC alkoxy, -CC 4 -alkylthio, -C 4 -haloalkoxy.
• R 4 and R 11 (which may be the same or different):
• CR 4 forms together with CR 11 a 5- or 6-membered alkylene or alkenylene ring, which may optionally be substituted, and in each case one or more methylene groups by oxygen, sulfur, -NH or -N (-CC 4 alkyl ), can be replaced.
• R 8 is hydrogen, -CC 8 -alkyl, C 3 -C 8 -alkenyl or C 3 -C 8 -alkynyl, -C-C 5 -alkylcarbonyl, where these radicals can each be mono- or polysubstituted by: halogen, hydroxy , Mercapto, carboxy, nitro, amino, cyano, C 1 -C 4 alkoxy, C 3 -C 6 alkenyloxy, C 3 -C 6 alkynyloxy, C 1 -C 4 alkylthio, C 1 -C 4 haloalkoxy, C ⁇ -C 4 -alkoxycarbonyl, C 3 -C 8 -alkylcarbonyl-alkyl, NHfCx ⁇ -alkyl), N (C ! -C 4 -alkyl) 2 , C 3 -C 8 -cycloalkyl,
• Phenoxy or phenyl where the aryl radicals mentioned can in turn be mono- or polysubstituted, for example mono- to three times by halogen, hydroxy, mercapto, carboxy, nitro, cyano, C 4 -alkyl, C haloalkyl, C ⁇ -C 4 -alkoxy, C 4 haloalkoxy, amino, NH (C ⁇ -C 4 - Alkyl), N (-CC 4 -alkyl) 2 , phenyl, or -CC 4 -alkylthio;
• Phenyl or naphthyl each of which may be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxy, amino, C ⁇ -C alkyl, C ⁇ -C 4 haloalkyl, C 1 -C 4 - alkoxy, C ⁇ - C -haloalkoxy, phenoxy, -CC 4 alkylthio, NH (-C 4 alkyl), N (-C 4 alkyl) 2 , dioxomethylene or dioxoethylene;
• C 8 -C 8 cycloalkyl where these radicals can each be mono- or polysubstituted by: halogen, hydroxy, mercapto, carboxy, nitro, cyano, C 4 -C 4 alkyl, C 2 -C 4 alkenyl,
• R 8 forms together with R 9 a to form a ring closed-sene C 3 -C 7 -alkylene chain which may be mono- or polysubstituted with C ⁇ -C 4 -alkyl, C 4 alkylthio, C ⁇ -C 4 -Alkoxy, -C-C 4 haloalkyl, C] _- C 4 haloalkoxy, and in which an alkylene group can be replaced by oxygen or sulfur, such as - (CH2.4-.
• R 9 is hydrogen, -CC 4 alkyl
• R 9 is linked to R 8 to form a ring, as indicated under R 8 .
• R 10 are hydrogen, C 8 alkyl, C 3 -C 8 -alkenyl or C 3 -C 8 alkynyl, where these radicals in each case may be mono- or polysubstituted by: halogen, hydroxy, mercapto, carboxy, nitro, amino, cyano, C 4 alkoxy, C 3 -C 6 alkenyloxy, C 3 -CG-alkynyloxy, C ⁇ -C 4 alkylthio, C ⁇ -C4-haloalkoxy, C ⁇ -C 4 alkoxycarbonyl, C 3 - C 8 -alkylcarbonylalkyl, carboxamide, CONH (-C-C 4 -alkyl), CON (C ⁇ -C 4 -alkyl) 2 , CONRiSRie, NH (C ⁇ -C 4 -alkyl), N (C ⁇ -C 4 -alkyl) 2 , C ß -Cs cycloalkyl, heteroaryloxy or hetero
• Phenyl or naphthyl each of which may be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxy, amino, C ⁇ -C 4 -alkyl, C 4 haloalkyl, C ⁇ -C4 alkoxy, C ⁇ - C 4 haloalkoxy, phenoxy, -C 4 alkylthio, NH (-C 4 alkyl), N (-C 4 alkyl) 2 , dioxomethylene or dioxoethylene;
• C 3 -Cg cycloalkyl where these radicals can each be mono- to trisubstituted by: halogen, hydroxy, mercapto, carboxy, nitro, cyano, C 1 -C 4 -alkyl, C 2 -C 4 -alkenyl, C 2 -C -Alkynyl, -C-C 4 alkoxy, -C-C 4 alkylthio, -C-C 4 -haloalkoxy.
• R 12 is hydrogen, -CC 4 alkyl; or NR 12 forms together with CR 4 a 5- or 6-membered alkylene or alkenylene ring which can be substituted one to three times with C 1 -C 4 -alkyl, and in which one or more methylene groups can be replaced by oxygen or sulfur .
• R 13 is hydrogen, halogen, -CC 4 alkyl, C 2 -C alkenyl, where these radicals can be substituted with halogen.
• R 14 is hydrogen, -CC 4 alkyl.
• R 15 and R 16 together form a closed C 3 -C 7 alkylene or C 4 -C 7 alkenylene chain, to which a phenyl ring is fused, which can be substituted one to three times by halogen, C 1 -C 4 -alkyl, C 4 alkylthio, C 1 -C 4 -alkoxy, C 4 haloalkyl, C ⁇ -C4-haloalkoxy, hydroxy, carboxy, amino.
• R 19 C ⁇ -C 4 -alkyl, C 4 alkylthio, C! -C 4 -alkoxy, which carry one of the following radicals: hydroxy, carboxy, -C-C 4 -alkoxycarbonyl, amino, NH (-C-C 4 -alkyl), N (-C-C 4 -alkyl) 2 , carboxamide or CON (-C-C 4 alkyl) 2nd
• An alkali metal is e.g. Lithium, sodium, potassium;
• An alkaline earth metal is, for example, calcium, magnesium, barium;
• C 3 -C 8 cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl;
• C 1 -C 4 -Halogenalkyl can be linear or branched such as fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, trichloromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2, 2, 2-trifluoroethyl, 2-chlorine 2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl or pentafluoroethyl;
• C 1 -C 4 -Halogenalkoxy can be linear or branched such as difluoromethoxy, trifluoromethoxy, chlorodifluoromethoxy, 1-fluoroethoxy, 2, 2-difluoroethoxy, 1, 1, 2, 2-tetrafluoroethoxy, 2,2,2-trifluoroethoxy , 2-chloro-1, 1, 2-trifluoroethoxy, 2-fluoroethoxy or pentafluoroethoxy;
• C 1 -C 4 -Alkyl can be linear or branched, such as methyl, ethyl, 1-propyl, 2-propyl, 2-methyl-2-propyl, 2-methyl-1-propyl, 1-butyl or 2-butyl;
• C 2 -C 4 alkenyl can be linear or branched, such as, for example, ethenyl, l-propen-3-yl, l-propen-3-yl, 1-propen-1-yl, 2-methyl-1-propenyl, 1- Butenyl or 2-butenyl;
• C 2 -C 4 alkynyl can be linear or branched, such as, for example, ethynyl, 1-propyn-1-yl, 1-propyn-3-yl, 1-butyn-4-yl or 2-butyn-4-yl;
• C ⁇ _C 4 alkoxy can be linear or branched such as methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy or 1, 1-dimethylethoxy;
• C 3 -C 6 alkenyloxy can be linear or branched, for example allyloxy, 2-buten-1-yloxy or 3-buten-2-yloxy;
• C 3 -C 6 alkynyloxy can be linear or branched, such as 2-propyn-1-yloxy, 2-butyn-1-yloxy or 3-butyn-2-yloxy;
• C 1 -C 4 -Alkylthio can be linear or branched such as methylthio, ethylthio, propylthio, 1-methylethylthio, butylthio, 1-methylpropylthio, 2-methylpropylthio or 1, 1-dimethylethylthio;
• C 1 -C 4 -alkylcarbonyl can be linear or branched, such as acetyl, ethylcarbonyl or 2-propylcarbonyl;
• C ⁇ -C 4 alkoxycarbonyl can be linear or branched such as Methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, i-propoxycarbonyl or n-butoxycarbonyl;
• C 3 -C 8 alkylcarbonylalkyl can be linear or branched, for example 2-oxo-prop-1-yl, 3-oxo-but-1-yl or 3-oxo-but-2-yl;
• C ⁇ -C 8 alkyl can be linear or branched such as -CC alkyl, pentyl, hexyl, heptyl or octyl;
• Halogen is e.g. Fluorine, chlorine, bromine, iodine.
• the invention further relates to those compounds from which the compounds of the formula I can be released (so-called prodrugs).
• prodrugs in which the release takes place under conditions such as those in certain body compartments, e.g. in the stomach, intestines, bloodstream, liver, predominate.
• the invention further relates to the use of the abovementioned carboxylic acid derivatives for the production of medicaments, in particular for the production of inhibitors for ET A and ET B receptors.
• the compounds I and also the intermediates for their preparation, e.g. II, can have one or more asymmetrically substituted carbon atoms.
• Such compounds can exist as pure enantiomers or pure diastereomers or as a mixture thereof.
• the use of an enantiomerically pure compound as the active ingredient is preferred.
• WO 96/11914 can be called.
• the compounds Ia according to the invention in which A is C 1 -C 4 -alkyl, azido, SR 10 or OR 10 and the other substituents have the meaning given under the general formula I can be prepared, for example, in such a way that the carboxylic acid derivatives of the general formula Ha, in which the substituents have the meaning given, with compounds of the general formula III to react.
• R 17 is halogen or R 18 -S0 2 , where R 18 can be C 1 -C 4 -alkyl, C ⁇ -C 4 -haloalkyl or phenyl.
• the reaction preferably takes place in an inert solvent or diluent with the addition of a suitable base, ie a base which brings about a deprotonation of the intermediate Ha, in a temperature range from room temperature to the boiling point of the solvent.
• solvents or diluents are aliphatic, alicyclic and aromatic hydrocarbons, each of which may optionally be chlorinated, such as, for example, hexane, cyclohexane, petroleum ether, ligroin, benzene, toluene, xylene, methylene chloride, chloroform, carbon tetrachloride, ethyl chloride and Trichlorethylene, ethers such as diisopropyl ether, dibutyl ether, methyl tert.
• chlorinated such as, for example, hexane, cyclohexane, petroleum ether, ligroin, benzene, toluene, xylene, methylene chloride, chloroform, carbon tetrachloride, ethyl chloride and Trichlorethylene, ethers such as diisopropyl ether, dibutyl ether, methyl tert.
• an alkali or alkaline earth metal hydride such as sodium hydride, potassium hydride or calcium hydride, a carbonate such as alkali metal carbonate, e.g. Sodium or potassium carbonate, an alkali or alkaline earth metal hydroxide such as sodium or potassium hydroxide, an organometallic compound such as butyllithium or an alkali metal such as lithium diisopropylamide or lithium amide.
• Carboxylic acids ie compounds of formula I in which R 1 is a group COOM, where M is an alkali metal cation or can be the equivalent of an alkaline earth metal cation.
• RW is a conventional nucleofugic leaving group, for example halogen such as chlorine, bromine, iodine or, where appropriate, aryl- or alkylsulfonyl substituted by halogen, alkyl or haloalkyl, such as, for example, toluenesulfonyl and methylsulfonyl or another equivalent leaving group.
• the preparation of the compounds I according to the invention requires the use of generally known protective group techniques.
• R 10 4-hydroxyphenyl
• the hydroxy group can first be protected as benzyl ether, which is then cleaved at a suitable stage in the reaction sequence.
• carboxylic acid derivatives of the general formula I - both as pure enantiomers or pure diastereomers or as a mixture thereof - are preferred, in which the substituents have the following meaning:
• R 2 and R 3 (which may be the same or different):
• Phenyl or naphthyl which can be substituted by one or more of the following radicals: halogen, cyano,
• -C 4 alkyl -CC-haloalkyl, -C-C 4 alkoxy, -C-C-haloalkoxy or Cj_-C 4 alkylthio; or Phenyl or naphthyl, which are ortho-bonded via a direct bond, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an S0 2 , NH or N (-C 4 alkyl) group
• C 5 -C 6 cycloalkyl where these radicals can each be mono- to trisubstituted by: halogen, -CC 4 -alkyl, -C-C 4 -alkoxy, -C-C 4 -alkylthio, -C-C 4 -haloalkoxy .
• R 4 and R 11 (which may be the same or different):
• CR 4 forms together with CR 11 a 5- or 6-membered alkylene or alkenylene ring which can be mono- to trisubstituted with C 1 -C 4 -alkyl and in which one to three methylene groups can be replaced by oxygen or sulfur.
• R 8 is hydrogen, C 1 -C 8 -alkyl, C 1 -C 5 -alkylcarbonyl, where these radicals can each be mono- to trisubstituted by: halogen, hydroxy, carboxy, amino, C 1 -C 4 -alkoxy, Cj_-C 4 - alkyl thio, C ⁇ -C4-haloalkoxy, C ⁇ -C alkoxycarbonyl, NH (C ⁇ -C4 alkyl), N (C 1 -C 4 alkyl) 2, C 5 -C 6 cycloalkyl, phenoxy or phenyl , where the aryl radicals mentioned 4-halo turn may be substituted once to three times by halogen, hydroxy, C ⁇ -C 4 -alkyl, C 4 haloalkyl, C ⁇ -C 4 -alkoxy, C alkoxy, amino, NH (C 1 -C 4 alkyl), N (C 1 -C 4 alkyl) 2 ,
• Phenyl or naphthyl which can each be mono- to trisubstituted by halogen, hydroxy, amino, C 1 -C 4 -alkyl, C ! -C 4 -haloalkyl, C 1 -C 4 -alkoxy, -C-C 4 -haloalkoxy, phenoxy, Cx-d-alkylthio, NH (C ⁇ -C 4 -alkyl), N (-C-C 4 -alkyl) 2 , Dioxomethylene or dioxoethylene;
• C 3 -C 8 cycloalkyl where these radicals can each be mono- to trisubstituted by: halogen, C ⁇ -C-alkyl, C ⁇ -C-alkoxy, C ⁇ -C 4 alkylthio, C ⁇ -C-haloalkoxy; or R 8 forms together with R 9 to form a ring closed a C 4 -C 6 -alkylene chain which can be mono- to trisubstituted substituted with C ⁇ -C 4 -alkyl, C 4 haloalkyl, and in which an alkylene group by Oxygen or sulfur can be replaced, such as - (CH 2 ) 4 -, - (CH 2 ) 5 -, - (CH 2 ) 6 -, - (CH 2 ) 2 -0- (CH 2 ) 2 -, - ( CH 2 ) 2 -S- (CH 2 ) 2 -.
• R 9 is hydrogen, -CC 4 alkyl
• R 9 is linked to R 8 to form a ring, as indicated under R 8 .
• R 10 is hydrogen, -CC 8 -alkyl, C 3 -C 8 -alkenyl or C 3 -C 8 -alkynyl, where these radicals can each be mono- to trisubstituted by: halogen, hydroxyl, mercapto, carboxy, amino, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylthio, C 4 -C 4 -haloalkoxy, C-C 4 -alkoxycarbonyl, carboxamide, CONH (C ⁇ -C 4 -alkyl), CON (C ⁇ -C - alkyl) 2 , CONR 15 R 16 , NH (C 1 -C 4 alkyl), N (-C-C 4 alkyl) 2 , C 5 -C 5 - cycloalkyl, phenoxy or phenyl, the aryl radicals in turn being mono- to trisubstituted can by halogen, hydroxy, -C-C
• Phenyl or naphthyl which in each case may be substituted one to three times by: halogen, hydroxy, amino, C ⁇ -C 4 -alkyl, C 4 haloalkyl, C ⁇ -C 4 -alkoxy, halogen-C alkoxy, C 1 -C 4 alkylthio, NH (C 1 -C 4 alkyl), N (C 1 -C 4 alkyl) 2 , dioxomethylene or dioxoethylene;
• R 12 is hydrogen, methyl
• NR 12 forms a 5- or 6-membered alkyl ring which can be mono- to trisubstituted by methyl.
• R 13 is hydrogen, halogen, -CC 4 alkyl, where these radicals can be mono- to trisubstituted by halogen.
• R 14 is hydrogen, methyl.
• R 15 and R 16 are hydrogen, methyl.
• R 15 and R 16 together form a closed ring
• Phenyl ring is annelated, such as 7-aza-bicyclo [4.2.0] -octa-1, 3, 5-triene, 2, 3-dihydroindole, indole,
• R 19 is methyl, ethyl, methoxy or ethoxy, any of the following
• R 2 and R 3 (which may be the same or different):
• Phenyl or naphthyl which in each case may be substituted one to three times by: halogen, hydroxy, C ⁇ -C 4 -alkyl, C 4 haloalkyl, C ⁇ -C 4 -alkoxy, C 4 -haloalkoxy, NH (C 1 -C 4 alkyl), N (C 1 -C 4 alkyl) 2, phenoxy or phenyl which is C ⁇ -C may be substituted up to three times by halogen, 4 -alkyl, C haloalkyl, C ⁇ -C 4 -alkoxy or -CC haloalkoxy; or
• Phenyl or naphthyl which are ortho-linked via a direct bond, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an S0, NH or N (-C 4 -alkyl) group;
• R 4 and R 11 (which may be the same or different): Hydrogen, halogen, -CC 4 alkyl, trifluoromethyl, hydroxymethylene, -C 4 alkoxy, -C 4 alkylthio, N (-C 4 alkyl) 2 ;
• CR 4 together with CR 11 forms a 5- or 6-membered alkylene or alkenylene ring which can be mono- to disubstituted by methyl and in which one methylene group can be replaced by oxygen;
• R 8 is hydrogen, C 1 -C 4 -alkyl, C 1 -C 4 alkylcarbonyl, where these radicals can each be mono- to trisubstituted by: halogen, hydroxy, carboxy, amino, C 1 -C 4 -alkoxy, C 1 -C 4 -Alkylthio, C !
• Phenyl which can be mono- to trisubstituted by halogen, hydroxy, C 1 -C 4 alkyl, trifluoromethyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, dioxomethylene or dioxoethylene;
• C 5 -C 6 cycloalkyl where these radicals can each be mono- to trisubstituted by: halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy;
• R 8 together with R 9 forms a closed CC 6 alkylene chain which can be mono- to trisubstituted with C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, and in which an alkylene group can be replaced by oxygen , such as - (CH 2 ) 4 -, - (CH 2 ) 5 -, - (CH 2 ) 6 -, - (CH 2 ) 2 -0- (CH 2 ) 2 -.
• R 9 is hydrogen, -CC alkyl
• R 9 is linked to R 8 as a ring under R 8 .
• R 10 is hydrogen, C 1 -C 4 -alkyl, where these radicals can each be mono- to trisubstituted by: halogen, hydroxy, carboxy, C 1 -C 4 -alkoxy, C ⁇ -C-alkoxycarbonyl, carboxamide, CONH (C ⁇ -C -Alkyl), CON (C ! -C 4 -alkyl) 2 , CONR 15 R 16 ,
• Phenyl mono- the C ⁇ -C C 1 -C C ⁇ C ⁇ -C-C may be substituted up to three times by halogen, hydroxy, 4 alkyl, 4 haloalkyl, 4 alkoxy, 4 alkylthio, NH (C ⁇ -C alkyl ), N (-C 4 alkyl) 2 , dioxomethylene or dioxoethylene;
• R 13 is hydrogen, halogen, -CC 4 alkyl, trifluoromethyl.
• R 15 and R 16 together form a C 3 -C 7 alkylene chain which is closed to a ring and to which a phenyl ring is fused, such as 2, 3-dihydroindole, indole, 1, 3-dihydroisoindole, 1, 2, 3, 4- Tetra-hydroquinoline, 1, 2, 3, 4-tetrahydroisoquinoline, where the phenyl ring can be substituted one to three times by halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy;
• R 19 methoxy or ethoxy, which carry one of the following radicals: hydroxy, carboxy, -CC 4 alkoxycarbonyl, amino, NH (C 1 -C 4 alkyl), N (C 1 -C 4 alkyl) 2 , carboxamide or CON (-C 4 alkyl) 2 .
• the compounds of the present invention offer new therapeutic potential for the treatment of hypertension, pulmonary hypertension, myocardial infarction, angina pectoris, arrhythmia acute / chronic kidney failure, chronic heart failure, renal failure, cerebral vasospasm, cerebral ischemia, subarachnoid hemorrhage, migraine, asthma, atheros - toxic shock, endotoxin-induced organ failure, intravascular coagulation, restenosis after angioplasty and by-pass surgery, benign prostate hyperplasia, ischemic and intoxication-related kidney failure or hypertension, metastasis and growth of mesenchymal tumors such as prostate cancer, contrast agents induced kidney failure, pancreatitis, gastrointestinal ulcers.
• the invention further relates to combinations of endothelin receptor antagonists of the formula I and inhibitors of the renin-angiotensin system.
• Inhibitors of the renin-angiotensin system are renin inhibitors, angiotensin II antagonists and angiotensin converting enzyme (ACE) inhibitors.
• Combinations of endothelin receptor antagonists of the formula I and ACE inhibitors are preferred.
• the invention further relates to combinations of endothelin receptor antagonists of the formula I and calcium antagonists such as verapamil.
• the invention further relates to combinations of endothelin receptor antagonists of the formula I and beta-blockers.
• the invention further relates to combinations of endothelin receptor antagonists of the formula I and diuretics.
• the invention further relates to combinations of endothelin receptor antagonists of the formula I and substances which block the action of VEGF (vascular endothelial growth factor).
• VEGF vascular endothelial growth factor
• substances which block the action of VEGF are, for example, antibodies directed against VEGF or specific binding proteins or also low molecular weight substances which can specifically inhibit VEGF release or receptor binding.
• the combinations mentioned above can be administered simultaneously or sequentially in time. They can be used both in a single pharmaceutical formulation or in separate formulations.
• the application form can also be different, for example the endothelin receptor antagonists can be administered orally and VEGF inhibitors parenterally.
• the ET A or ET B receptor-expressing CHO cells were in DMEM NUT MIX F 12 medium (Gibco, No. 21331-020) with 10% fetal calf serum (PAA Laboratories GmbH, Linz, No. A15-022) , 1 M glutamine (Gibco No. 25030-024), 100 U / ml penicillin and 100 ⁇ g / ml streptomycin (Gibco, Sigma No. P-0781) increased. After 48 hours, the cells were washed with PBS and incubated with 0.05% trypsin-containing PBS at 37 ° C for 5 minutes. After that, with medium neutralized and the cells collected by centrifugation at 300 xg.
• the cells were adjusted to a concentration of 10 8 cells / ml buffer (50 M Tris-HCL buffer, pH 7.4) and then disintegrated by ultrasound (Branson Sonifier 250, 40-70 seconds / constant / output 20) .
• the membranes were incubated in incubation buffer (50 mM Tris-HCl, pH 7.4 with 5 mM MnCl 2 , 40 mg / ml bacitracin and 0.2% BSA) in a concentration of 50 ⁇ g Protein suspended per test batch and incubated at 25 ° C with 25 pM [125J] ETi (ET A receptor test) or 25 pM [125J] -ET 3 (ET B receptor test) in the presence and absence of test substance.
• the non-specific binding was determined to be 10 ⁇ 7 ME i.
• test animals were given the test compounds i.v. 30 min before the ETI administration. injected (1 ml / kg). To determine the ET antagonistic properties, the blood pressure changes in the test animals were compared with those in the control animals.
• big endothelin (20 ⁇ g / kg, Appl. Vol. 0.5 ml / kg) or ETI (0.3 ⁇ g / kg, Appl. Vol. 0.5 ml / kg) is given intravenously. Blood pressure and heart rate are continuously recorded over 30 minutes. The significant and persistent changes in blood pressure are calculated as the area under the curve (AUC). To determine the antagonistic effect of the test substances, the AUC of the substance-treated animals is compared with the AUC of the control animals.
• the compounds according to the invention can be administered in the usual way orally or parenterally (subcutaneously, intravenously, intramuscularly, intraperitoneally). It can also be applied with vapors or sprays through the nasopharynx.
• the dosage depends on the age, condition and weight of the patient and on the type of application.
• the daily dose of active substance is between approximately 0.5 and 100 mg / kg body weight when administered orally and between approximately 0.1 and 10 mg / kg body weight when administered parenterally.
• the new compounds can be used in the customary pharmaceutical application forms, solid or liquid, e.g. as tablets, film-coated tablets, capsules, powders, granules, dragees, suppositories, solutions, ointments, creams or sprays. These are manufactured in the usual way.
• the active ingredients can be processed with the usual pharmaceutical auxiliaries such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, retardants, antioxidants and / or propellants (see H. Sucker et al. : Pharmaceutical Technology, Thieme-Verlag, Stuttgart, 1991).
• the administration forms obtained in this way normally contain the active ingredient in an amount of 0.1 to 90% by weight.

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Urology & Nephrology (AREA)
• Pulmonology (AREA)
• Vascular Medicine (AREA)
• Hospice & Palliative Care (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Thiazole And Isothizaole Compounds (AREA)
• Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=7848772

Family Applications (1)

Country Status (23)

Families Citing this family (3)

Family Cites Families (1)

• 1997
  • 1997-11-14 DE DE19750529A patent/DE19750529A1/de not_active Withdrawn
• 1998
  • 1998-11-04 PL PL98340756A patent/PL340756A1/xx not_active Application Discontinuation
  • 1998-11-04 SK SK493-2000A patent/SK4932000A3/sk unknown
  • 1998-11-04 JP JP2000521084A patent/JP2001523671A/ja active Pending
  • 1998-11-04 ID IDW20000882A patent/ID24819A/id unknown
  • 1998-11-04 HU HU0004341A patent/HUP0004341A3/hu unknown
  • 1998-11-04 CN CN98811085A patent/CN1278805A/zh active Pending
  • 1998-11-04 IL IL13546198A patent/IL135461A0/xx unknown
  • 1998-11-04 BR BR9814157-0A patent/BR9814157A/pt not_active IP Right Cessation
  • 1998-11-04 TR TR2000/01365T patent/TR200001365T2/xx unknown
  • 1998-11-04 CA CA002308746A patent/CA2308746A1/en not_active Abandoned
  • 1998-11-04 EP EP98958900A patent/EP1037883A1/de not_active Withdrawn
  • 1998-11-04 US US09/530,382 patent/US6358983B1/en not_active Expired - Fee Related
  • 1998-11-04 WO PCT/EP1998/007026 patent/WO1999025701A1/de not_active Application Discontinuation
  • 1998-11-04 AU AU14878/99A patent/AU752165B2/en not_active Ceased
  • 1998-11-04 NZ NZ504289A patent/NZ504289A/en unknown
  • 1998-11-04 KR KR1020007005207A patent/KR20010032083A/ko not_active Application Discontinuation
  • 1998-11-09 AR ARP980105651A patent/AR017581A1/es not_active Application Discontinuation
  • 1998-11-13 CO CO98067231A patent/CO4990973A1/es unknown
  • 1998-11-13 ZA ZA9810425A patent/ZA9810425B/xx unknown
  • 1998-11-13 HR HR19750529.5A patent/HRP980591A2/hr not_active Application Discontinuation
• 2000
  • 2000-04-27 NO NO20002154A patent/NO20002154L/no not_active Application Discontinuation
  • 2000-05-04 BG BG104400A patent/BG104400A/xx unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events